Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal. Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement...
You must be a Standard 1 Year member to access this content.
Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Royalty Pharma in connection with its development funding. Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary...
You must be a Standard 1 Year member to access this content.
